1. Home
  2. CASY vs INCY Comparison

CASY vs INCY Comparison

Compare CASY & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Casey's General Stores Inc.

CASY

Casey's General Stores Inc.

HOLD

Current Price

$571.40

Market Cap

21.0B

Sector

Miscellaneous

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$104.94

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CASY
INCY
Founded
1959
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Commercial Physical & Biological Resarch
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.0B
17.0B
IPO Year
N/A
1993

Fundamental Metrics

Financial Performance
Metric
CASY
INCY
Price
$571.40
$104.94
Analyst Decision
Buy
Buy
Analyst Count
9
20
Target Price
$565.78
$90.71
AVG Volume (30 Days)
294.4K
2.3M
Earning Date
12-09-2025
10-28-2025
Dividend Yield
0.40%
N/A
EPS Growth
13.46
3878.02
EPS
15.58
5.90
Revenue
$16,410,268,000.00
$4,813,105,000.00
Revenue This Year
$10.98
$19.33
Revenue Next Year
$6.01
$10.47
P/E Ratio
$36.61
$17.70
Revenue Growth
8.74
18.09
52 Week Low
$372.09
$53.56
52 Week High
$573.76
$109.28

Technical Indicators

Market Signals
Indicator
CASY
INCY
Relative Strength Index (RSI) 62.65 62.26
Support Level $539.51 $100.30
Resistance Level $564.61 $107.61
Average True Range (ATR) 12.75 3.01
MACD 4.10 -0.57
Stochastic Oscillator 95.95 49.03

Price Performance

Historical Comparison
CASY
INCY

About CASY Casey's General Stores Inc.

Casey's General Stores Inc serves as convenience store chain with its 2,900 locations, positioned in the Midwest United States. About half of Casey's stores are located in rural towns with populations under 5,000. While fueling stations serve as a key traffic driver, about two-thirds of the company's gross profit stems from in-store sales of grocery items, prepared meals, and general merchandise. Casey's owns more than 90% of its stores and operates the majority of its warehousing and distribution processes internally.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: